Cargando…
Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Curcumin has demonstrated anti-inflammatory properties and has been investigated as an adjuvant therapy of ulcerative colitis (UC). The scope of this study was to systematically review and meta-analyze the efficacy of oral curcumin administration as an adjuvant therapy of UC. MEDLINE, Cochrane/CENTR...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266508/ https://www.ncbi.nlm.nih.gov/pubmed/30424514 http://dx.doi.org/10.3390/nu10111737 |
_version_ | 1783375855534211072 |
---|---|
author | Grammatikopoulou, Maria G. Gkiouras, Konstantinos Theodoridis, Xenophon Asteriou, Eleni Forbes, Alastair Bogdanos, Dimitrios P. |
author_facet | Grammatikopoulou, Maria G. Gkiouras, Konstantinos Theodoridis, Xenophon Asteriou, Eleni Forbes, Alastair Bogdanos, Dimitrios P. |
author_sort | Grammatikopoulou, Maria G. |
collection | PubMed |
description | Curcumin has demonstrated anti-inflammatory properties and has been investigated as an adjuvant therapy of ulcerative colitis (UC). The scope of this study was to systematically review and meta-analyze the efficacy of oral curcumin administration as an adjuvant therapy of UC. MEDLINE, Cochrane/CENTRAL, ClinicalTrials.gov, WHO-ICT Registry, EMBASE and grey literature were searched for relevant randomized controlled trials (RCTs). The primary outcome was clinical remission (attainment) and the secondary outcome was clinical response (maintenance/failure). Risk of bias was assessed with the Cochrane tool. Odds ratios (OR) were calculated with a Mantel-Haenszel (M-H) random effects model and with a beta-binomial (B-B) random effects model when zero events/cells occurred. Four RCTs met the criteria, but one was removed from the analyses due to inconsistency in protocol details. With the M-H method, treatment with curcumin was significantly superior to placebo in attaining remission in the per-protocol (PP) analysis (OR = 5.83, 95%CI = 1.24–27.43), but not in the intention-to-treat (ITT) analysis (OR = 4.33, 95%CI = 0.78–24.00). However, with the more accurate B-B method, both analyses were insignificant (for PP OR = 4.26, 95%CI = 0.59–31.00, for ITT OR = 3.80, 95%CI = 0.55–26.28). Based on the current available evidence, oral curcumin administration does not seem superior to placebo in attaining remission in patients with UC. Future RCTs should be planned more cautiously with sufficient size and adhere to the ITT analysis in all outcomes. |
format | Online Article Text |
id | pubmed-6266508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-62665082018-12-06 Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Grammatikopoulou, Maria G. Gkiouras, Konstantinos Theodoridis, Xenophon Asteriou, Eleni Forbes, Alastair Bogdanos, Dimitrios P. Nutrients Review Curcumin has demonstrated anti-inflammatory properties and has been investigated as an adjuvant therapy of ulcerative colitis (UC). The scope of this study was to systematically review and meta-analyze the efficacy of oral curcumin administration as an adjuvant therapy of UC. MEDLINE, Cochrane/CENTRAL, ClinicalTrials.gov, WHO-ICT Registry, EMBASE and grey literature were searched for relevant randomized controlled trials (RCTs). The primary outcome was clinical remission (attainment) and the secondary outcome was clinical response (maintenance/failure). Risk of bias was assessed with the Cochrane tool. Odds ratios (OR) were calculated with a Mantel-Haenszel (M-H) random effects model and with a beta-binomial (B-B) random effects model when zero events/cells occurred. Four RCTs met the criteria, but one was removed from the analyses due to inconsistency in protocol details. With the M-H method, treatment with curcumin was significantly superior to placebo in attaining remission in the per-protocol (PP) analysis (OR = 5.83, 95%CI = 1.24–27.43), but not in the intention-to-treat (ITT) analysis (OR = 4.33, 95%CI = 0.78–24.00). However, with the more accurate B-B method, both analyses were insignificant (for PP OR = 4.26, 95%CI = 0.59–31.00, for ITT OR = 3.80, 95%CI = 0.55–26.28). Based on the current available evidence, oral curcumin administration does not seem superior to placebo in attaining remission in patients with UC. Future RCTs should be planned more cautiously with sufficient size and adhere to the ITT analysis in all outcomes. MDPI 2018-11-12 /pmc/articles/PMC6266508/ /pubmed/30424514 http://dx.doi.org/10.3390/nu10111737 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Grammatikopoulou, Maria G. Gkiouras, Konstantinos Theodoridis, Xenophon Asteriou, Eleni Forbes, Alastair Bogdanos, Dimitrios P. Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
title | Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
title_full | Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
title_fullStr | Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
title_full_unstemmed | Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
title_short | Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
title_sort | oral adjuvant curcumin therapy for attaining clinical remission in ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266508/ https://www.ncbi.nlm.nih.gov/pubmed/30424514 http://dx.doi.org/10.3390/nu10111737 |
work_keys_str_mv | AT grammatikopouloumariag oraladjuvantcurcumintherapyforattainingclinicalremissioninulcerativecolitisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT gkiouraskonstantinos oraladjuvantcurcumintherapyforattainingclinicalremissioninulcerativecolitisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT theodoridisxenophon oraladjuvantcurcumintherapyforattainingclinicalremissioninulcerativecolitisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT asterioueleni oraladjuvantcurcumintherapyforattainingclinicalremissioninulcerativecolitisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT forbesalastair oraladjuvantcurcumintherapyforattainingclinicalremissioninulcerativecolitisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT bogdanosdimitriosp oraladjuvantcurcumintherapyforattainingclinicalremissioninulcerativecolitisasystematicreviewandmetaanalysisofrandomizedcontrolledtrials |